{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:35:07Z","timestamp":1777865707482,"version":"3.51.4"},"reference-count":107,"publisher":"The Royal Society","issue":"1949","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["093956\/Z\/10\/C"],"award-info":[{"award-number":["093956\/Z\/10\/C"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Quantifying therapeutic responses in clinical malaria is easier than for most other infections as the intraerythrocytic parasites can be counted by microscopy or estimated using quantitative PCR. In treating the blood-stage of malaria, between 107 and 1013 parasites undergo a first-order decline in densities at a rate determined by the concentrations and potency of the antimalarial drug. A simple conceptual framework based on total intravascular parasite biomass and standard sigmoid concentration\u2013effect relationships for parasite killing explains most, but not all, aspects of antimalarial therapeutic responses, and it has proved very useful in designing chemoprevention and treatment regimens and in understanding the selection and spread of resistance. Drugs acting on younger circulating ring-stage asexual parasites (artemisinins, cipargamin, ganaplacide) provide rapid parasite clearance, which translates into faster clinical recoveries and a life-saving benefit in severe malaria. Artemisinin-sensitive Plasmodium falciparum densities decline with a half-life (PC1\/2) of usually less than 5 h. Many antimalarial drugs are eliminated slowly and provide protracted exposures, which allows full treatment to be administered in 3 days, and also provides chemosuppression of newly acquired infections for 1 month. Greater availability of drug measurement in malaria-endemic areas would facilitate the field assessment of antimalarial drugs.<\/jats:p>\n                  <jats:p>This article is part of the Theo Murphy meeting issue \u2018Evaluating anti-infective drugs\u2019.<\/jats:p>","DOI":"10.1098\/rstb.2024.0339","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:18:12Z","timestamp":1777533492000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of the pharmacodynamic properties of antimalarial drugs"],"prefix":"10.1098","volume":"381","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-1978","authenticated-orcid":false,"given":"Nicholas John","family":"White","sequence":"first","affiliation":[{"name":"Mahidol University 1 , ,","place":["Bangkok, Thailand"],"department":["Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine"]},{"name":"University of Oxford 2 , ,","place":["Oxford, UK"],"department":["Nuffield Department of Medicine"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"175","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026043003180243100_R1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1098\/rspb.2002.2241","article-title":"The de novo selection of drug-resistant malaria parasites","volume":"270","author":"White","year":"2003","journal-title":"Proc. R. Soc. Lond. B"},{"key":"2026043003180243100_R2","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1128\/AAC.00287-13","article-title":"Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization","volume":"57","author":"White","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1017\/S0031182001001202","article-title":"Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection","volume":"124","author":"Simpson","year":"2002","journal-title":"Parasitology"},{"key":"2026043003180243100_R4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(13)60024-0","article-title":"Malaria","volume":"383","author":"White","year":"2014","journal-title":"Lancet"},{"key":"2026043003180243100_R5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41467-024-44962-4","article-title":"Revisiting the Plasmodium sporozoite inoculum and elucidating the efficiency with which malaria parasites progress through the mosquito","volume":"15","author":"Kanatani","year":"2024","journal-title":"Nat. Commun."},{"key":"2026043003180243100_R6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0035-9203(90)90367-N","article-title":"Highly efficient dry season transmission of malaria in Thailand","volume":"84","author":"Rosenberg","year":"1990","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"2026043003180243100_R7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4269\/ajtmh.1991.45.574","article-title":"The number of sporozoites produced by individual malaria oocysts","volume":"45","author":"Rosenberg","year":"1991","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2026043003180243100_R8","first-page":"404","article-title":"Sporozoite transmission by Anopheles freeborni and Anopheles gambiae experimentally infected with Plasmodium falciparum","volume":"8","author":"Beier","year":"1992","journal-title":"J. Am. Mosq. Control Assoc."},{"key":"2026043003180243100_R9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/CMR.00051-10","article-title":"Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination","volume":"24","author":"Bousema","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"2026043003180243100_R10","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-13-483","article-title":"Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria","volume":"13","author":"White","year":"2014","journal-title":"Malar. J."},{"key":"2026043003180243100_R11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1473-3099(12)70198-6","article-title":"Primaquine to prevent transmission of falciparum malaria","volume":"13","author":"White","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"2026043003180243100_R12","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/infdis\/jiv596","article-title":"Numerical distributions of parasite densities during asymptomatic malaria","volume":"213","author":"Imwong","year":"2016","journal-title":"J. Infect. Dis."},{"key":"2026043003180243100_R13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(18)30046-X","article-title":"The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study","volume":"18","author":"Nguyen","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"2026043003180243100_R14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.pt.2022.05.008","article-title":"The assessment of antimalarial drug efficacy in vivo","volume":"38","author":"White","year":"2022","journal-title":"Trends Parasitol."},{"key":"2026043003180243100_R15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0014-4894(83)90007-3","article-title":"Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation","volume":"55","author":"Chulay","year":"1983","journal-title":"Exp. Parasitol."},{"key":"2026043003180243100_R16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4269\/ajtmh.2004.71.711","article-title":"A histidine-rich protein 2-based malaria drug sensitivity assay for field use","volume":"71","author":"Noedl","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2026043003180243100_R17","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1128\/AAC.00367-06","article-title":"Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from Africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration","volume":"50","author":"Kaddouri","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R18","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-015-0940-8","article-title":"Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry","volume":"14","author":"Wirjanata","year":"2015","journal-title":"Malar. J."},{"key":"2026043003180243100_R19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1128\/AAC.01868-12","article-title":"Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia","volume":"57","author":"Witkowski","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R20","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1128\/AAC.01924-13","article-title":"Laboratory detection of artemisinin-resistant Plasmodium falciparum","volume":"58","author":"Chotivanich","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R21","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-023-08381-y","article-title":"Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs","volume":"23","author":"Dembele","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"2026043003180243100_R22","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1128\/AAC.03666-14","article-title":"A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs","volume":"58","author":"Ruecker","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/BF01451737","article-title":"Die Wirkung des Plasmochins auf die Vogelmalaria","volume":"14","author":"Roehl","year":"1926","journal-title":"Naturwissenschaften"},{"key":"2026043003180243100_R24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0031182021002134","article-title":"Current status of experimental models for the study of malaria","volume":"149","author":"Simwela","year":"2022","journal-title":"Parasitology"},{"key":"2026043003180243100_R25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.124.002218","article-title":"Primaquine-5,6-orthoquinone is directly hemolytic to older G6PD deficient RBCs in a humanized mouse model","volume":"391","author":"Dziewulska-Cronk","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026043003180243100_R26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00261-18","article-title":"Investigating sulfoxide-to-sulfone conversion as a prodrug strategy for a phosphatidylinositol 4-kinase inhibitor in a humanized mouse model of malaria","volume":"62","author":"Gibhard","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pt.2009.10.007","article-title":"The murine cerebral malaria phenomenon","volume":"26","author":"White","year":"2010","journal-title":"Trends Parasitol."},{"key":"2026043003180243100_R28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/0300985815583098","article-title":"A review of Plasmodium coatneyi\u2013macaque models of severe malaria","volume":"52","author":"Lombardini","year":"2015","journal-title":"Vet. Pathol."},{"key":"2026043003180243100_R29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.30802\/AALAS-CM-24-000019","article-title":"Overview of Plasmodium spp. and animal models in malaria research","volume":"74","author":"Gozalo","year":"2024","journal-title":"Comp. Med."},{"key":"2026043003180243100_R30","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4269\/ajtmh.1986.35.1077","article-title":"Compatibility of relapse patterns of Plasmodium cynomolgi infections in rhesus monkeys with continuous cyclical development and hypnozoite concepts of relapse","volume":"35","author":"Schmidt","year":"1986","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2026043003180243100_R31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/520154","article-title":"Double-blind, randomized, placebo-controlled assessment of chloroquine\/primaquine prophylaxis for malaria in nonimmune Colombian soldiers","volume":"29","author":"Soto","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"2026043003180243100_R32","first-page":"391","article-title":"The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain)","volume":"46","author":"Arnold","year":"1955","journal-title":"J. Lab. Clin. Med."},{"key":"2026043003180243100_R33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0035-9203(61)90103-1","article-title":"Induced primaquine resistance in vivax malaria","volume":"55","author":"Arnold","year":"1961","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"2026043003180243100_R34","doi-asserted-by":"crossref","first-page":"5485706","DOI":"10.1080\/00034983.1970.11686660","article-title":"A method for demonstrating drug action on exo-erythrocytic stages","volume":"64","author":"Gregory","year":"1970","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"2026043003180243100_R35","first-page":"119","article-title":"Chemoprophylaxis of malaria: underlying principles and their realization","volume":"50","author":"Wernsdorfer","year":"1990","journal-title":"Med. Trop."},{"key":"2026043003180243100_R36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1172\/JCI101956","article-title":"PROCEDURES USED AT STATEVILLE PENITENTIARY FOR THE TESTING OF POTENTIAL ANTIMALARIAL AGENTS 1","volume":"27","author":"Alving","year":"1948","journal-title":"J. Clin. Invest."},{"key":"2026043003180243100_R37","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00479-17","article-title":"Controlled human malaria infection: applications, advances, and challenges","volume":"86","author":"Stanisic","year":"2018","journal-title":"Infect. Immun."},{"key":"2026043003180243100_R38","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1128\/JCM.01057-14","article-title":"High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias","volume":"52","author":"Imwong","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"2026043003180243100_R39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/427243","article-title":"Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites","volume":"191","author":"Bejon","year":"2005","journal-title":"J. Infect. Dis."},{"key":"2026043003180243100_R40","unstructured":"World Health Organization, Global Malaria Programme. 2023Guidelines for malaria. Seehttps:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria."},{"key":"2026043003180243100_R41","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1128\/AAC.48.11.4271-4280.2004","article-title":"In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up","volume":"48","author":"Stepniewska","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R42","first-page":"85","article-title":"Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies","volume":"73","author":"Viriyakosol","year":"1995","journal-title":"Bull. World Health Organ."},{"key":"2026043003180243100_R43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4269\/ajtmh.1999.60.14","article-title":"Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand","volume":"60","author":"Brockman","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2026043003180243100_R44","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1128\/AAC.00159-07","article-title":"Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials","volume":"51","author":"Greenhouse","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R45","volume-title":"Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas","author":"World Health Organisation","year":"2021"},{"key":"2026043003180243100_R46","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54203-0","article-title":"Amplicon deep sequencing improves Plasmodium falciparum genotyping in clinical trials of antimalarial drugs","volume":"9","author":"Gruenberg","year":"2019","journal-title":"Sci. Rep."},{"key":"2026043003180243100_R47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64830-z","article-title":"Probabilistic classification of late treatment failure in uncomplicated falciparum malaria","volume":"16","author":"Mehra","year":"2025","journal-title":"Nat. Commun."},{"key":"2026043003180243100_R48","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1172\/JCI21682","article-title":"Antimalarial drug resistance","volume":"113","author":"White","year":"2004","journal-title":"J. Clin. Investig."},{"key":"2026043003180243100_R49","unstructured":"World Health Organization\n          . 2015Guidelines for the treatment of malaria. Seehttps:\/\/iris.who.int\/bitstream\/handle\/10665\/162441\/9789241549127_eng.pdf."},{"key":"2026043003180243100_R50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pt.2008.01.006","article-title":"Simplified antimalarial therapeutic monitoring: using the day-7 drug level?","volume":"24","author":"White","year":"2008","journal-title":"Trends Parasitol."},{"key":"2026043003180243100_R51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jmsacl.2023.12.004","article-title":"A high-throughput LC-MS\/MS assay for piperaquine from dried blood spots: improving malaria treatment in resource-limited settings","volume":"31","author":"Blessborn","year":"2024","journal-title":"J. Mass Spectrom. Adv. Clin. Lab."},{"key":"2026043003180243100_R52","unstructured":"World Health Organization\n          . 2024Tools for monitoring antimalarial drug efficacy. Seehttps:\/\/www.who.int\/teams\/global-malaria-programme\/case-management\/drug-efficacy-and-resistance\/tools-for-monitoring-antimalarial-drug-efficacy."},{"key":"2026043003180243100_R53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12936-021-03980-z","article-title":"Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis","volume":"21","author":"WorldWide Antimalarial Resistance Network Methodology Study Group","year":"2022","journal-title":"Malar. J."},{"key":"2026043003180243100_R54","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-8-253","article-title":"Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance","volume":"8","author":"White","year":"2009","journal-title":"Malar. J."},{"key":"2026043003180243100_R55","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz264","article-title":"Optimal duration of follow-up for assessing antimalarial efficacy in pregnancy: a retrospective analysis of a cohort followed up until delivery on the Thailand\u2013Myanmar border","volume":"6","author":"Saito","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"2026043003180243100_R56","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-10-297","article-title":"Determinants of relapse periodicity in Plasmodium vivax malaria","volume":"10","author":"White","year":"2011","journal-title":"Malar. J."},{"key":"2026043003180243100_R57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-12-397900-1.00002-5","article-title":"Relapse","volume":"80","author":"White","year":"2012","journal-title":"Adv. Parasitol."},{"key":"2026043003180243100_R58","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1086\/512241","article-title":"Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites","volume":"195","author":"Imwong","year":"2007","journal-title":"J. Infect. Dis."},{"key":"2026043003180243100_R59","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1086\/512242","article-title":"Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals","volume":"195","author":"Chen","year":"2007","journal-title":"J. Infect. Dis."},{"key":"2026043003180243100_R60","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13412-x","article-title":"Resolving the cause of recurrent Plasmodium vivax malaria probabilistically","volume":"10","author":"Taylor","year":"2019","journal-title":"Nat. Commun."},{"key":"2026043003180243100_R61","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-10-278","article-title":"The parasite clearance curve","volume":"10","author":"White","year":"2011","journal-title":"Malar. J."},{"key":"2026043003180243100_R62","article-title":"Malaria parasite clearance","volume":"16","author":"White","year":"2017","journal-title":"Malar. J."},{"key":"2026043003180243100_R63","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/infdis\/jiy673","article-title":"Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria","volume":"219","author":"Intharabut","year":"2019","journal-title":"J. Infect. Dis."},{"key":"2026043003180243100_R64","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-10-339","article-title":"Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator","volume":"10","author":"Flegg","year":"2011","journal-title":"Malar. J."},{"key":"2026043003180243100_R65","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-12-410","article-title":"A robust design for identification of the parasite clearance estimator","volume":"12","author":"Jamsen","year":"2013","journal-title":"Malar. J."},{"key":"2026043003180243100_R66","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2026043003180243100_R67","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of artemisinin-resistant malaria in Africa","volume":"385","author":"Balikagala","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2026043003180243100_R68","first-page":"1","article-title":"Severe malaria","volume":"19","author":"World Health Organization","year":"2014","journal-title":"Trop. Med. Int. Health"},{"key":"2026043003180243100_R69","article-title":"Artesunate versus quinine for treating severe malaria","volume":"2019","author":"Sinclair","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"2026043003180243100_R70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn5040","article-title":"Improving the diagnosis of severe malaria in African children using platelet counts and plasma Pf HRP2 concentrations","volume":"14","author":"Watson","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"2026043003180243100_R71","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34678-8","article-title":"The prognostic and diagnostic value of intraleukocytic malaria pigment in patients with severe falciparum malaria","volume":"13","author":"Srinamon","year":"2022","journal-title":"Nat. Commun."},{"key":"2026043003180243100_R72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001297","article-title":"Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement","volume":"9","author":"Hendriksen","year":"2012","journal-title":"PLoS Med."},{"key":"2026043003180243100_R73","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.4269\/ajtmh.20-0186","article-title":"Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis","volume":"103","author":"Commons","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"2026043003180243100_R74","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2401024121","article-title":"Modeling the within-host dynamics of Plasmodium vivax hypnozoite activation: an analysis of the SPf66 vaccine trial","volume":"121","author":"Mehra","year":"2024","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026043003180243100_R75","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-021-03700-7","article-title":"Anti-malarial drug effects on parasite dynamics in vivax malaria","volume":"20","author":"White","year":"2021","journal-title":"Malar. J."},{"key":"2026043003180243100_R76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003561","article-title":"The prevention and treatment of Plasmodium vivax malaria","volume":"18","author":"Chu","year":"2021","journal-title":"PLoS Med."},{"key":"2026043003180243100_R77","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00011-19","article-title":"8-Aminoquinoline therapy for latent malaria","volume":"32","author":"Baird","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"2026043003180243100_R78","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","article-title":"Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial","volume":"394","author":"Taylor","year":"2019","journal-title":"Lancet"},{"key":"2026043003180243100_R79","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1473-3099(23)00430-9","article-title":"Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis","volume":"24","author":"Commons","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"2026043003180243100_R80","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1111\/bcp.15219","article-title":"Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials","volume":"88","author":"White","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026043003180243100_R81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004411","article-title":"Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis","volume":"21","author":"Fadilah","year":"2024","journal-title":"PLoS Med."},{"key":"2026043003180243100_R82","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S1473-3099(15)00479-X","article-title":"Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial","volume":"16","author":"Dicko","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"2026043003180243100_R83","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1473-3099(18)30044-6","article-title":"Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial","volume":"18","author":"Dicko","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"2026043003180243100_R84","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00853-24","article-title":"Transmission-blocking activities of artesunate, chloroquine, and methylene blue on Plasmodium vivax gametocytes","volume":"68","author":"Chaumeau","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R85","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cpt.1716","article-title":"Safety, pharmacokinetics, and mosquito-lethal effects of ivermectin in combination with dihydroartemisinin-piperaquine and primaquine in healthy adult Thai subjects","volume":"107","author":"Kobylinski","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026043003180243100_R86","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/AAC.41.7.1413","article-title":"Assessment of the pharmacodynamic properties of antimalarial drugs in vivo","volume":"41","author":"White","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R87","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01423-20","article-title":"Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum","volume":"65","author":"McCarthy","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R88","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005311","article-title":"Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention","volume":"6","author":"Bergstrand","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2026043003180243100_R89","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02476-17","article-title":"Characterizing blood-stage antimalarial drug MIC values in vivo using reinfection patterns","volume":"62","author":"Watson","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R90","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/trstmh\/trad042","article-title":"A proposed method of grading malaria chemoprevention efficacy","volume":"117","author":"White","year":"2023","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"2026043003180243100_R91","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12483-4","article-title":"Split dosing of artemisinins does not improve antimalarial therapeutic efficacy","volume":"7","author":"White","year":"2017","journal-title":"Sci. Rep."},{"key":"2026043003180243100_R92","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/jac\/dkad219","article-title":"An artesunate pharmacometric model to explain therapeutic responses in Falciparum malaria","volume":"78","author":"Saralamba","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"2026043003180243100_R93","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1086\/656476","article-title":"Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure","volume":"202","author":"Teuscher","year":"2010","journal-title":"J. Infect. Dis."},{"key":"2026043003180243100_R94","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-10-56","article-title":"Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure","volume":"10","author":"Codd","year":"2011","journal-title":"Malar. J."},{"key":"2026043003180243100_R95","first-page":"e02256","article-title":"Kelch mutations in Plasmodium falciparum protein K13 do not modulate dormancy after artemisinin exposure and sorbitol selection in vitro","volume":"62","author":"Breglio","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003180243100_R96","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00109-24","article-title":"Artemisinin-resistant malaria","volume":"37","author":"White","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"2026043003180243100_R97","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/infdis\/jiv358","article-title":"A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609","volume":"213","author":"Zhang","year":"2016","journal-title":"J. Infect. Dis."},{"key":"2026043003180243100_R98","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1086\/315718","article-title":"The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria","volume":"182","author":"Chotivanich","year":"2000","journal-title":"J. Infect. Dis."},{"key":"2026043003180243100_R99","unstructured":"Medicines for Malaria Venture\n          . 2025Target product profiles (TPPs) and Target Candidate Profiles (TCPs) for malaria medicines. Seehttps:\/\/www.mmv.org\/research-development\/information-225scientists\/target-product-profiles-target-candidate-profiles (accessed1-January-2025)."},{"key":"2026043003180243100_R100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12936-021-03821-z","article-title":"SERCAP: is the perfect the enemy of the good?","volume":"20","author":"White","year":"2021","journal-title":"Malar. J."},{"key":"2026043003180243100_R101","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/cpt.3041","article-title":"Evidence based optimal dosing of intravenous artesunate in children with severe Falciparum malaria","volume":"114","author":"Haghiri","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026043003180243100_R102","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-11-418","article-title":"Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common","volume":"11","author":"White","year":"2012","journal-title":"Malar. J."},{"key":"2026043003180243100_R103","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83433","article-title":"The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis","volume":"11","author":"Watson","year":"2022","journal-title":"eLife"},{"key":"2026043003180243100_R104","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/0002-9343(82)90337-0","article-title":"Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria","volume":"73","author":"White","year":"1982","journal-title":"Am. J. Med."},{"key":"2026043003180243100_R105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004312","article-title":"Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria","volume":"20","author":"Watson","year":"2023","journal-title":"PLoS Med."},{"key":"2026043003180243100_R106","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(21)00692-7","article-title":"Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial","volume":"22","author":"Peto","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"2026043003180243100_R107","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","volume":"395","author":"van der Pluijm","year":"2020","journal-title":"Lancet"}],"container-title":["Philosophical Transactions B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0339\/6135527\/rstb.2024.0339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0339\/6135527\/rstb.2024.0339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:18:26Z","timestamp":1777533506000},"score":1,"resource":{"primary":{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article\/381\/1949\/20240339\/481545\/Assessment-of-the-pharmacodynamic-properties-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":107,"journal-issue":{"issue":"1949","published-online":{"date-parts":[[2026,4,30]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1098\/rstb.2024.0339","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"20240339"}}